Century Therapeutics (IPSC) Competitors $0.61 +0.00 (+0.16%) As of 02:27 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IPSC vs. PRQR, MNPR, ELDN, ESPR, VYGR, DERM, DMAC, OGI, CYBN, and FDMTShould you be buying Century Therapeutics stock or one of its competitors? The main competitors of Century Therapeutics include ProQR Therapeutics (PRQR), Monopar Therapeutics (MNPR), Eledon Pharmaceuticals (ELDN), Esperion Therapeutics (ESPR), Voyager Therapeutics (VYGR), Journey Medical (DERM), DiaMedica Therapeutics (DMAC), Organigram (OGI), Cybin (CYBN), and 4D Molecular Therapeutics (FDMT). These companies are all part of the "pharmaceutical products" industry. Century Therapeutics vs. Its Competitors ProQR Therapeutics Monopar Therapeutics Eledon Pharmaceuticals Esperion Therapeutics Voyager Therapeutics Journey Medical DiaMedica Therapeutics Organigram Cybin 4D Molecular Therapeutics ProQR Therapeutics (NASDAQ:PRQR) and Century Therapeutics (NASDAQ:IPSC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations, valuation and community ranking. Which has stronger earnings & valuation, PRQR or IPSC? ProQR Therapeutics has higher earnings, but lower revenue than Century Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProQR Therapeutics$18.97M10.70-$30.43M-$0.35-5.51Century Therapeutics$114.90M0.45-$136.67M-$0.29-2.08 Do analysts recommend PRQR or IPSC? ProQR Therapeutics presently has a consensus target price of $8.00, indicating a potential upside of 314.51%. Century Therapeutics has a consensus target price of $4.20, indicating a potential upside of 597.67%. Given Century Therapeutics' higher possible upside, analysts plainly believe Century Therapeutics is more favorable than ProQR Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ProQR Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Century Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is PRQR or IPSC more profitable? ProQR Therapeutics has a net margin of -134.31% compared to Century Therapeutics' net margin of -4,837.73%. Century Therapeutics' return on equity of -61.66% beat ProQR Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ProQR Therapeutics-134.31% -71.58% -19.70% Century Therapeutics -4,837.73%-61.66%-31.78% Does the MarketBeat Community favor PRQR or IPSC? ProQR Therapeutics received 296 more outperform votes than Century Therapeutics when rated by MarketBeat users. However, 70.49% of users gave Century Therapeutics an outperform vote while only 62.09% of users gave ProQR Therapeutics an outperform vote. CompanyUnderperformOutperformProQR TherapeuticsOutperform Votes33962.09% Underperform Votes20737.91% Century TherapeuticsOutperform Votes4370.49% Underperform Votes1829.51% Do insiders & institutionals believe in PRQR or IPSC? 32.7% of ProQR Therapeutics shares are held by institutional investors. Comparatively, 50.2% of Century Therapeutics shares are held by institutional investors. 8.4% of ProQR Therapeutics shares are held by company insiders. Comparatively, 6.8% of Century Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media refer more to PRQR or IPSC? In the previous week, ProQR Therapeutics had 2 more articles in the media than Century Therapeutics. MarketBeat recorded 7 mentions for ProQR Therapeutics and 5 mentions for Century Therapeutics. ProQR Therapeutics' average media sentiment score of 1.28 beat Century Therapeutics' score of -0.19 indicating that ProQR Therapeutics is being referred to more favorably in the media. Company Overall Sentiment ProQR Therapeutics Positive Century Therapeutics Neutral Which has more risk and volatility, PRQR or IPSC? ProQR Therapeutics has a beta of 0.31, suggesting that its share price is 69% less volatile than the S&P 500. Comparatively, Century Therapeutics has a beta of 1.77, suggesting that its share price is 77% more volatile than the S&P 500. SummaryProQR Therapeutics beats Century Therapeutics on 11 of the 19 factors compared between the two stocks. Get Century Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IPSC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IPSC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IPSC vs. The Competition Export to ExcelMetricCentury TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$51.87M$3.11B$5.60B$8.63BDividend YieldN/A1.57%5.28%4.18%P/E Ratio-0.3333.0627.2520.01Price / Sales0.45469.00412.71157.94Price / CashN/A168.6838.2534.64Price / Book0.203.437.124.70Net Income-$136.67M-$72.35M$3.24B$248.05M7 Day Performance6.93%7.86%2.75%2.62%1 Month Performance14.73%18.41%9.00%6.32%1 Year Performance-81.53%-16.84%31.41%13.78% Century Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IPSCCentury Therapeutics2.5312 of 5 stars$0.61+0.2%$4.20+591.8%-81.4%$52.31M$114.90M-0.33170Gap UpPRQRProQR Therapeutics3.0248 of 5 stars$1.78+7.2%$8.00+349.4%-0.5%$187.28M$18.97M-5.56180Positive NewsAnalyst RevisionMNPRMonopar Therapeutics3.2435 of 5 stars$30.01-5.4%$55.33+84.4%+750.4%$183.51MN/A-15.2310News CoveragePositive NewsELDNEledon Pharmaceuticals2.623 of 5 stars$3.06+2.0%$12.50+308.5%+3.4%$183.24MN/A-1.5210Gap UpESPREsperion Therapeutics4.1863 of 5 stars$0.92+8.1%$6.25+580.4%-58.3%$182.07M$259.57M-1.44200Options VolumeAnalyst RevisionVYGRVoyager Therapeutics4.4242 of 5 stars$3.29+20.1%$13.39+307.0%-61.0%$182.06M$66.96M4.63100Trending NewsAnalyst RevisionHigh Trading VolumeDERMJourney Medical2.3209 of 5 stars$7.81-3.1%$9.88+26.4%+21.7%$181.94M$56.24M-8.3190Positive NewsShort Interest ↑High Trading VolumeDMACDiaMedica Therapeutics1.35 of 5 stars$4.17+1.5%$8.00+91.8%+54.4%$178.82MN/A-7.4520Short Interest ↑OGIOrganigram0.6373 of 5 stars$1.31-3.0%N/A-7.3%$175.39M$194.09M-3.45860Positive NewsCYBNCybin3.0235 of 5 stars$8.10+1.8%$86.00+961.7%N/A$173.96MN/A-1.8550News CoverageAnalyst RevisionFDMT4D Molecular Therapeutics2.977 of 5 stars$3.75+3.6%$29.56+688.1%-81.3%$173.72M$23K-1.32120Analyst ForecastAnalyst Revision Related Companies and Tools Related Companies PRQR Alternatives MNPR Alternatives ELDN Alternatives ESPR Alternatives VYGR Alternatives DERM Alternatives DMAC Alternatives OGI Alternatives CYBN Alternatives FDMT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IPSC) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Century Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Century Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
